PLRX Pliant Therapeutics Gross Profit Rate

FDA breakthrough therapy designation and a 100% patient retention rate in clinical trials create strong momentum for Pliant Therapeutics (PLRX). Marginal gross profit visualizes this optimism, where 0.00 reflects the baseline level of the metric. Prospects rely on the market launch of drugs targeting lung and liver fibrosis, although fierce competition with tech giants for leadership in this niche maintains risks.
Analytical breakdowns and data insights for company Pliant Therapeutics Inc (PLRX)

For Pliant Therapeutics (PLRX), which relies on external capacities for drug production, the gross margin reflects the efficiency of managing outsourcing costs relative to generated revenue. An analysis of gross margin profitability allows for an assessment of the revenue share remaining after direct production costs, which is critical for determining the business's capital intensity and avoiding overpayment for the asset during a strategic valuation.